Hormone Therapy for Advanced Prostate Cancer

The identification of probable sources of androgen and strategies for lowering their levels are essential to the characterization of advanced PC. The first question that can be asked during the construction of a protocol for the use of hormone therapy in prostate cancer is when, in which forms, and in which stages of prostate cancer this type of therapy can be most beneficial. The first hormone therapy for prostate cancer are LHRH agonists and LHRH antagonists. Antiandrogens are a broad class of drugs that neutralize the effects of testosterone and dihydrotestosterone, blocking androgen receptors (AR). They are used in conjunction with ADT, most frequently with LHRH agonists. Total androgen blockade (TAB) or combined androgen blockade are terms used to describe this form of treatment. The current protocols are presented based on the results of clinical investigations on a large number of patients, based on the results of main and secondary outcomes. Total androgen blockade (TAB) with the addition of antiandrogens (AR antagonists or androgen synthesis blockers) to basic ADT therapy (often LHRH antagonists) may be a “gold standard” for treating castration-resistant prostate cancer. Clinical research has demonstrated that TAB is more successful than ADT.